Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis
Anti-PD-1/PD-L1 antibodies are widely used in anti-cancer therapy. While they have improved cancer prognoses, immune-related adverse events, which can cause acute kidney injury (AKI), cannot be ignored. The purpose of this retrospective cohort study was to assess the incidence, risk factors, and pro...
Saved in:
| Main Authors: | Qianqian Lou, Jianguang Gong, Binxian Ye, Rizhen Yu, Shuangshan Bu, Yiwen Li, Bin Zhu, Lina Shao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2238823 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023-12-01) -
Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1
by: Barry D. Hock, et al.
Published: (2025-05-01) -
PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01) -
Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
by: Shaohua Li, et al.
Published: (2024-10-01) -
Production of Antibodies Binding Murine Nuclear PD-L1
by: Valentina Kostenko, et al.
Published: (2024-04-01)